New long-term data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one ...

"Eli Lilly’s Omvoh achieves 91% Crohn’s steroid-free remission at three years" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Omvoh ® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn's disease (CD) In VIVID-1, Omvoh ® showed statistically significant and clinically ...

Crohn’s patients taking Omvoh saw three-years of remission when taking Omvoh, according to new long-term data released by Eli Lilly. 1 The data is the result of the Phase 3 VIVID-2 open label ...

Eli Lilly and Co. LLY on Thursday released promising long-term data regarding its treatment for Crohn’s disease. This news comes as the company reported that more than 90% of patients maintained ...

(RTTNews) - Eli Lilly and Co. (LLY), on Friday, announced that most patients with moderately to severely active Crohn's disease treated with Omvoh for two years, experienced sustained clinical ...

Eli Lilly and Co.’s approval for Omvoh to treat moderate to severe Crohn’s disease in adults marks the Indianapolis company’s growing presence in the treatment of inflammatory bowel disease. This ...

Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission At four years, ...

Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation. 2,3 "Many ...